802 Dose intensity (DI) chemotherapy improves disease free survival in elderly aggressive non-Hodgkin's lymphoma (NHL) patients treated with conventional chop

1995 ◽  
Vol 31 ◽  
pp. S168
Author(s):  
H. Gómez ◽  
S. Santillana ◽  
L. Casanova ◽  
S. Valdivia ◽  
J. Otero ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Disease Free Survival ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

Prolonged disease-free survival in pediatric non-hodgkin's lymphoma using ifosfamide-containing combination chemotherapy

2006 ◽  
Vol 9 (4-5) ◽  
pp. 281-286 ◽  
Author(s):  
Nazli Gad-El-Mawla ◽  
M. R. Hamza ◽  
S. Abdel-Hadi ◽  
O. El-Tannir ◽  
M. H. Hussein ◽  
...  
Keyword(s):  
Combination Chemotherapy ◽  
Hodgkin’S Lymphoma ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

Comparison of doxorubicin and mitoxantrone in the treatment of elderly patients with advanced diffuse non-Hodgkin's lymphoma using CHOP versus CNOP chemotherapy.

1995 ◽  
Vol 13 (10) ◽  
pp. 2530-2539 ◽  
Author(s):  
P Sonneveld ◽  
M de Ridder ◽  
H van der Lelie ◽  
K Nieuwenhuis ◽  
H Schouten ◽  
...  
Keyword(s):  
Elderly Patients ◽  
Hodgkin’S Lymphoma ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Phase Iii ◽  
Serum Lactate Dehydrogenase ◽  
High Grade ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

PURPOSE AND METHODS A prospective, randomized, multicenter phase III trial was performed to investigate the feasibility of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy in elderly patients ( > or = 60 years) with advanced non-Hodgkin's lymphoma (NHL) of intermediate- and high-grade malignancy, and to compare the tolerance and efficacy of doxorubicin versus mitoxantrone (CHOP v CNOP). RESULTS Of 157 enrolled patients, 148 were eligible and 145 were assessable for response. Thirty-one percent of CNOP and 45% of CHOP patients completed six cycles without dose reduction. The cumulative normalized dose-intensity (NDI) was 92% with CHOP and 90% with CNOP after six cycles. The overall complete response (CR) rates were 49% and 31% in CHOP- and CNOP-treated patients, respectively (P = .03). Survival with CNOP was significantly worse as compared with CHOP (P = .03). Lymphoma-specific survival was significantly better in CHOP-treated patients (P = .034) At 3 years, 42% of CHOP and 26% of CNOP patients were alive. Additional unfavorable prognostic factors at diagnosis were high serum lactate dehydrogenase (LDH) level, bulky mass, and low performance status, but not age. The median disease-free intervals of complete responders were 27 (CHOP) and 15 (CNOP) months, respectively. Considering the complete group of patients, at 3 years 17% of CHOP and 13% of CNOP patients were alive and disease-free (P = .12). Common toxicity criteria (CTC) grade > or = 2 with CNOP and CHOP was not different. CONCLUSION CHOP is well tolerated in elderly patients with advanced intermediate- or high-grade NHL and its NDI is not seriously impaired. Treatment with CHOP (doxorubicin) results in better CR and survival rates than CNOP (mitoxantrone). CHOP should be recommended for elderly patients with high-risk NHL.

scholarly journals Potential for Prolonged Disease-free Survival Following Combination Chemotherapy of Non-Hodgkin’s Lymphoma

Blood ◽  
1974 ◽  
Vol 43 (2) ◽  
pp. 181-189 ◽  
Author(s):  
Philip S. Schein ◽  
Bruce A. Chabner ◽  
George P. Canellos ◽  
Robert C. Young ◽  
Costan Berard ◽  
...  
Keyword(s):  
Complete Remission ◽  
Median Survival ◽  
Combination Chemotherapy ◽  
Hodgkin’S Lymphoma ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin's Lymphoma ◽  
Well Differentiated ◽  
Disease Free

Abstract The evaluation of the results of CVP and MOPP chemotherapy in 80 patients with advanced stages of non-Hodgkin’s lymphoma indicates that 36 (45%) achieved a complete remission. Twenty-eight per cent of the entire group of patients remain free of disease for periods ranging from 4 mo to over 7 yr, with a projected median duration of complete remission of 3½ yr. Significant differences in prognosis relative to histologic categories were found. Well-differentiated and nodular histology were positive determinants for improved median survival, confirming the over-all clinical validity of the Rappaport classification system for the non-Hodgkin’s lymphomas. The median survival for patients in the most clinically aggressive subgroups with diffuse histology is inferior to those with nodular patterns or well-differentiated cells. In this study it was demonstrated that it was possible to achieve a significant number of complete remissions even in the most aggressive histologic subgroups using combination chemotherapy, and these responses can be correlated with an extended disease-free survival without further therapy.

Chemotherapeutic results and prognostic factors of patients with advanced non-Hodgkin's lymphoma treated with VEPA or VEPA-M.

1988 ◽  
Vol 6 (1) ◽  
pp. 128-141 ◽  
Author(s):  
M Shimoyama ◽  
K Ota ◽  
M Kikuchi ◽  
K Yunoki ◽  
S Konda ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Survival Rate ◽  
T Cell ◽  
Hodgkin’S Lymphoma ◽  
Survival Rates ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
Non Hodgkin's Lymphoma ◽  
Disease Free

One hundred sixty-three patients with advanced non-Hodgkin's lymphoma including adult T cell leukemia/lymphoma (ATL) were treated from 1981 to 1983 with VEPA (vincristine, cyclophosphamide, prednisolone, and doxorubicin) or VEPA-M (VEPA plus methotrexate) in randomized fashion after stratification by surface marker. The complete response (CR) rate and the 4-year survival rate of patients treated with VEPA-M was 62.2% and 36.9%, respectively, while for those treated with VEPA the rates were 51.9% and 26.6, respectively. The difference was not statistically significant, but pretreatment characteristics predictive for response and survival were interesting. Three factors, leukemic change, poor performance status (PS), and T cell marker, were negatively associated with both CR and survival rates, and high-grade pathology was adversely associated with survival rate in a multivariate analysis. These prognostic factors are somewhat different from those in Western lymphomas. This may be reflection of major differences in patients' characteristics between Japanese and Western lymphomas: in this study, there was a high incidence of T cell lymphoma/leukemia (50%) including ATL (33%), leukemic manifestation (34%), poor PS (34%), and a low incidence of follicular lymphoma (9%). The statistically significant three factors for both CR and survival rates were used to construct a model containing eight categories of patients at increasing risk for poor response and shortened survival. These categories were divided into four groups, with respective CR and 4-year survival rates of 91% and 73%, 67% and 35%, 27% and 7%, and 10% and 5%. Ninety-three patients in whom CR was induced by VEPA or VEPA-M therapy were evaluated for prognostic factors predictive for disease-free survival. A shorter period (less than 28 days) required to achieve CR, a clinical diagnosis of ATL, and a lower hemoglobin level were found to affect disease-free survival adversely. These results have important implications for both the design of prospective randomized therapeutic trials and the determination of optimal therapy for individual patients.

scholarly journals 18FDG-PET following treatment as valid predictor for disease-free survival in Hodgkin’s lymphoma

2001 ◽  
Vol 12 (1) ◽  
pp. 29-37 ◽  
Author(s):  
M. de Wit ◽  
K.H. Bohuslavizki ◽  
R. Buchert ◽  
D. Bumann ◽  
M. Clausen ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Disease Free Survival ◽  
Hodgkin's Lymphoma ◽  
Free Survival ◽  
18Fdg Pet ◽  
Valid Predictor ◽  
Disease Free

scholarly journals Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: Application to LNH-87 protocol

1993 ◽  
Vol 4 (8) ◽  
pp. 651-656 ◽  
Author(s):  
E. Lepage ◽  
C. Gisselbrecht ◽  
C. Haioun ◽  
C. Sebban ◽  
H. Tilly ◽  
...  
Keyword(s):  
Hodgkin’S Lymphoma ◽  
Prognostic Significance ◽  
Dose Intensity ◽  
Hodgkin's Lymphoma ◽  
Relative Dose Intensity ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma

High-dose carmustine, etoposide, and cisplatin and autologous bone marrow transplantation for relapsed and refractory lymphoma.

1992 ◽  
Vol 10 (11) ◽  
pp. 1682-1689 ◽  
Author(s):  
H M Lazarus ◽  
P Crilley ◽  
N Ciobanu ◽  
R J Creger ◽  
R M Fox ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Lymphoma ◽  
Hodgkin’S Disease ◽  
Autologous Bone Marrow Transplantation ◽  
Autologous Bone Marrow ◽  
Hodgkin's Lymphoma ◽  
Non Hodgkin’S Lymphoma ◽  
Non Hodgkin's Lymphoma ◽  
Autologous Bone ◽  
Disease Free

PURPOSE We determined the toxicity and efficacy of a new preparative autologous bone marrow transplantation (ABMT) regimen in patients with relapsed or refractory non-Hodgkin's lymphoma or Hodgkin's disease. PATIENTS AND METHODS Forty-four non-Hodgkin's lymphoma and 35 Hodgkin's disease patients 16 to 63 years of age were given intravenous carmustine (BCNU) 600 to 1,050 mg/m2, etoposide 2,400 to 3,000 mg/m2, and cisplatin 200 mg/m2 (BEP) and ABMT. Fifty-nine patients also received 15 to 20 Gy local radiation (involved-field radiotherapy [RI]) to active or previously bulky (> 5 cm) disease sites. RESULTS Nonhematologic toxicities included nausea, vomiting, high-tone hearing loss, stomatitis, esophagitis, diarrhea, and hepatic and pulmonary toxicity. Two patients died within 40 days of marrow infusion as a result of sepsis and one patient died 7 months after transplant as a result of pulmonary fibrosis. Complete remissions (CRs) were noted in 72% (n = 57) of patients (n = 33 non-Hodgkin's lymphoma; n = 24 Hodgkin's disease). Forty patients (51%) remained alive and disease-free (n = 24 non-Hodgkin's lymphoma; n = 16 Hodgkin's disease) at a median of 17 (range, 8 to 57) months after marrow reinfusion. CONCLUSIONS This regimen seems to be effective for relapsed lymphoma patients whose disease continues to exhibit chemotherapy sensitivity (16 of 24 [67%] disease-free). Furthermore, this regimen seems to be effective in patients who have never attained a CR (seven of 19 [37%] disease-free).

Sign in / Sign up

Export Citation Format

Share Document